Sec Form 3 Filing - Busch Matthew C. @ AMGEN INC - 2023-08-14

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Busch Matthew C. 2. Issuer Name and Ticker or Trading Symbol AMGEN INC [ AMGN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) VP, Finance & CAO (Last) (First) (Middle) ONE AMGEN CENTER DRIVE 3. Date of Earliest Transaction (MM/DD/YY) 08/14/2023 (Street) THOUSAND OAKS, CA91320 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 4,596 ( 1 ) ( 2 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Nqso (Right to Buy) $ 177.46 04/27/2020( 3 ) 04/27/2028 Common Stock 1,257 D Nqso (Right to Buy) $ 177.31 05/03/2021( 4 ) 05/03/2029 Common Stock 1,476 D Nqso (Right to Buy) $ 236.36 05/05/2022( 5 ) 05/05/2030 Common Stock 1,558 D Nqso (Right to Buy) $ 239.64 04/30/2023( 6 ) 04/30/2031 Common Stock 1,086 D Nqso (Right to Buy) $ 230.92 05/02/2024( 7 ) 05/02/2032 Common Stock 1,753 D Nqso (Right to Buy) $ 235.97 05/02/2025( 8 ) 05/02/2033 Common Stock 2,508 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Busch Matthew C. ONE AMGEN CENTER DRIVE THOUSAND OAKS, CA91320 VP, Finance & CAO Signatures /s/ Matthew C. Busch 08/21/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 64 RSUs which will vest on 5/5/2024; 84 RSUs which will vest in installments of 41 on 4/30/2024 and 43 on 4/30/2025; 175 RSUs which will vest on 11/5/2023; 1,496 RSUs which will vest in installments of 493 on 11/5/2023, 494 on 11/5/2024 and 509 on 11/5/2025; 214 RSUs which will vest in installments of 70 on 5/2/2024, 71 on 5/2/2025, and 73 on 5/2/2026; and 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. ( 2 )These shares include 126 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. ( 3 )1,257 of these non-qualified stock options have vested and are exercisable. ( 4 )1,476 of these non-qualified stock options have vested and are exercisable. ( 5 )1,028 of these non-qualified stock options have vested and 530 will vest and become exercisable on 5/5/2024. ( 6 )358 of these non-qualified stock options have vested and the remaining options will vest and become exercisable in installments of 358 on 4/30/2024 and 370 on 4/30/2025. ( 7 )These non-qualified stock options will vest and become exercisable in two installments of 578 on 5/2/2024 and 5/2/2025 and one installment of 597 on 5/2/2026. ( 8 )These non-qualified stock options will vest and become exercisable in installments of 827 on 5/2/2025, 828 on 5/2/2026 and 853 on 5/2/2027.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.